While levels of total and IGF-1R have been identified as poor prognostic factors in breast cancer [21], levels of IGF-1R expression have not been shown to predict benefit from anti-IGF therapeutics (reviewed in [22]). The gene discussed is IGF1; the disease is breast cancer.